Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

749.79
+3.430.46%
Post-market: 744.00-5.7900-0.77%19:22 EST
Volume:766.00K
Turnover:573.81M
Market Cap:78.80B
PE:18.03
High:751.99
Open:746.55
Low:743.33
Close:746.36
52wk High:790.98
52wk Low:476.49
Shares:105.10M
Float Shares:103.30M
Volume Ratio:0.78
T/O Rate:0.74%
Dividend:3.52
Dividend Rate:0.47%
EPS(TTM):41.59
EPS(LYR):40.90
ROE:15.19%
ROA:6.16%
PB:2.55
PE(LYR):18.33

Loading ...

Regeneron price target raised to $660 from $650 at Citi

TIPRANKS
·
Oct 13

Regeneron Reports Dramatic Hearing Improvements in Children With Genetic Deafness in DBOTO Gene Therapy Trial

Reuters
·
Oct 12

Regeneron (REGN) Is Up After FDA Approves Libtayo as First Adjuvant Immunotherapy for High-Risk CSCC

Simply Wall St.
·
Oct 12

Regeneron Pharma Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Oct 11

Is Regeneron at a Turning Point After 43% Drop and FDA Eye Drug Approval News?

Simply Wall St.
·
Oct 10

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Oct 10

Cantor Fitzgerald Keeps Their Buy Rating on Regeneron (REGN)

TIPRANKS
·
Oct 09

Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Sysmex (SSMXF)

TIPRANKS
·
Oct 09

Trump Excludes Generics From Big Pharma Tariff Plan

Dow Jones
·
Oct 09

BRIEF-Libtayo Approved In The U.S. For Adjuvant Treatment Of Cutaneous Squamous Cell Carcinoma

Reuters
·
Oct 09

Regeneron Shares Hit Session Low, Last Down 1.5% at $574.53

THOMSON REUTERS
·
Oct 09

Regeneron Pharmaceuticals Shares Lose Ground After Spiking Higher, Last up 0.3% Around $585.13 After Touching a High of $605

THOMSON REUTERS
·
Oct 09

Regeneron says FDA approves PD-1 inhibitor Libtayo

TIPRANKS
·
Oct 09

FDA approves Regeneron Libtayo as adjuvant treatment for high risk CSCC after surgery and radiation

Reuters
·
Oct 09

Regeneron Pharmaceuticals Inc: Approved Supplemental Biologics License Application (Sbla) Did Not Include Catalent Indiana, Llc as a Filling Site

THOMSON REUTERS
·
Oct 09

Libtayo® (Cemiplimab-Rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (Cscc) With a High Risk of Recurrence After Surgery and Radiation

THOMSON REUTERS
·
Oct 09

RBC Capital Keeps Their Hold Rating on Regeneron (REGN)

TIPRANKS
·
Oct 09